Advertisement
Original Contribution
JAMA. 1991;265(21):2831-2835. doi: 10.1001/jama.1991.03460210077033

Treatment of Acute Migraine With Subcutaneous Sumatriptan

  1. Roger K. Cady, MD;
  2. Jeanette K. Wendt, MD;
  3. John R. Kirchner, MD;
  4. Joseph D. Sargent, MD;
  5. John F. Rothrock;
  6. Harold Skaggs, Jr, MD
  1. From the Shealy Institute for Comprehensive Health Care, Springfield, Mo (Dr Cady); Department of Neurology, Health Science Center, University of Arizona, Tucson (Dr Wendt); the Migraine Treatment Clinic, Omaha, Neb (Dr Kirchner); Headache and Internal Medicine Research Center, Menninger, Topeka, Kan (Dr Sargent); Department of Neurology, University of California at San Diego Medical Center (Dr Rothrock); Neurology Section, Center for Clinical Research, Austin, Tex (Dr Skaggs); on behalf of the US Sumatriptan Research Group.; Dr Cady owns stock in Glaxo Pharmaceuticals Inc.

Abstract

Sumatriptan succinate, a 5-HT1D receptor agonist, constricts human cranial arteries. Two parallel-group trials for treatment of acute migraines were conducted in the United States. Adult patients were randomized and given either 6 mg of sumatriptan succinate subcutaneously (n = 734) or placebo (n = 370). At 1 hour, sumatriptan was significantly more effective than placebo in reducing moderate or severe headache pain to mild or no pain (70% vs 22%), in completely relieving headaches (49% vs 9%), and in improving clinical disability (76% vs 34%). Sumatriptan also reduced nausea and photophobia significantly better than placebo. Patients with residual migraines received another injection; those who had originally received sumatriptan received either a second active injection (n = 187) or placebo (n = 178), while those who had received placebo received a second placebo injection (n = 335). Statistical evidence for benefit of second sumatriptan injection is absent. Adverse events associated with sumatriptan were tingling, dizziness, warm-hot sensations, and injection-site reactions. Sumatriptan is effective and well tolerated in patients with acute migraine.

(JAMA. 1991;265:2831-2835)

Footnotes

  • Reprint requests to Shealy Institute for Comprehensive Health Care, 1328 E Evergreen St, Springfield, MO 65803 (Dr Cady).

« Previous | Next Article »Table of Contents

More in JAMA & Archives Journals